Search for dissertations about: "Tommy Andersson"
Showing result 6 - 10 of 19 swedish dissertations containing the words Tommy Andersson.
-
6. Atrial fibrillation and cause of death, sex differences in mortality, and anticoagulation treatment in low-risk patients
Abstract : Background: Atrial fibrillation (AF) is the most common arrhythmia but information on cause of death in patients with AF is sparse, and whether individuals at low risk of cerebral infarction (CVL) should receive antico-agulant medication is controversial. Studies of sex differences with respect to mortality risk have shown conflicting results. READ MORE
-
7. Adipose tissue as an active organ : blood flow regulation and tissue-specific glucocorticoid metabolism
Abstract : Background: Despite advances in the treatment of atherosclerosis, cardiovascular disease is the leading cause of death worldwide. With the population getting older and more obese, the burden of cardiovascular disease may further increase. READ MORE
-
8. Estrogen and Glucocorticoid Metabolism
Abstract : Background: Cardiovascular disease (CVD) is the leading cause of death among women in Sweden. The risk of CVD increases rapidly after the menopause. A major contributing factor may be the redistribution of adipose tissue, from the peripheral to central depots, associated with menopause. READ MORE
-
9. Scrutinizing a policy ambition to make business out of science : Lessons from Taiwan
Abstract : The promotion of industrial development and economic growth is a vital issue for governments all over the world. The ideals guiding policymakers in their endeavours are that innovations based on new and advanced knowledge are central for industrial and economic development. READ MORE
-
10. Studies of the Biology of Intrathecal Treatment in Progressive MS
Abstract : Background: Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease, affecting the central nervous system (CNS). About 85% of afflicted present with a relapsing-remitting form of the disease (RRMS), for which a breakthrough in treatment was made in 2008 with rituximab, an antibody directed towards CD20, a surface antigen on B-cells. READ MORE